Using SGA Medications in Cancer Care: What Actually Happens
I ran into this question a lot when I was on the oncology ward. People hear "therapy" and picture something active against the tumor itself. With SGA — second-generation antipsychotics — that isn't the case. These drugs don't treat cancer. They manage symptoms that show up alongside it or as a side effect of treatment. That distinction matters because patients and families sometimes come in expecting a different outcome than what these medications can deliver. The ones you see most often in this setting are quetiapine, olanzapine, and aripiprazole. Each has a slightly different profile, which is why we don't just pick one at random. Quetiapine tends to be the go-to for delirium and nausea because it's sedating and hits the serotonin and dopamine receptors in a way that calms things down without as much extrapyramidal risk. Olanzapine shows up a lot for chemotherapy-induced nausea that isn't responding to the standard antiemetics. Aripiprazole comes in when you need something less sedating but still need to address agitation or appetite issues.
What Sga Therapy For Cancer Actually Looks Like in Practice
The word "therapy" here is doing a lot of work. In oncology, SGA use falls under supportive care or palliative management. A typical scenario: a patient on high-dose dexamethasone for brain metastases develops steroid-induced psychosis or severe agitation. That's when quetiapine 25 to 50 mg at night enters the picture. Another common one: a patient on FOLFOX regimen who can't keep anything down despite ondansetron, aprepitant, and dexamethasone. Adding olanzapine 5 to 10 mg orally dissolving tab at bedtime can make a noticeable difference within a few days. Here's the part nobody tells you upfront. The doses we use in cancer patients are almost always lower than what psychiatrists use for primary psychiatric conditions. We're not targeting a psychotic disorder in the same way. We're trying to knock down delirium severity enough that the patient can rest and the family can function. Sometimes 25 mg of quetiapine is the ceiling. Sometimes the patient is so sensitive that even 12.5 mg causes problematic daytime sedation. You learn quickly that starting low and going slow isn't advice here — it's the only approach that works. I remember one case where a patient with pancreatic cancer was getting quetiapine for delirium. We were titrating up carefully. At 50 mg they were stable but sleepy. At 75 mg they became almost unarousable for most of the day. The problem was that their albumin was 2.1 and their liver function was impaired from the disease process. Free drug levels were higher than we expected even at what looked like a moderate dose. That's a pharmacokinetic issue that doesn't show up in the package insert. You catch it by watching the patient, not by reading a reference.
Which SGA and When
Quetiapine is the most commonly used agent in this population. It's available as a regular tablet, an orally disintegrating tablet, and an extended-release formulation. The ODT version is useful when swallowing is a problem or when the patient is nauseated. The XR version gives smoother blood levels but takes longer to reach steady state, which matters when you need rapid titration for acute agitation. Olanzapine has a stronger antiemetic mechanism through 5-HT3 and dopamine antagonism. That's why it shows up in the NCCN guidelines for chemotherapy-induced nausea and vomiting as an add-on option. The standard dose range for this indication is 2.5 to 10 mg daily. Most patients respond somewhere around 5 mg. The sedation is real but often acceptable since it comes at night. Metabolic effects like glucose elevation and weight gain are more relevant over longer treatment periods than in the short palliative courses we often see. Aripiprazole is the odd one out here because it's a partial agonist rather than a full antagonist. That makes it less sedating but also less predictable for delirium management. I've used it successfully in patients who needed to stay alert enough for cognitive testing or who were already heavily sedated by other medications. The dose range is typically 1 to 5 mg daily. It takes longer to reach steady state — about a week — so if you need something immediately you won't see the full effect right away.
Get the Full Details
Risperidone comes up occasionally but I tend to avoid it in frail cancer patients. The extrapyramidal side effects are more common at the doses we use, and the QT prolongation risk adds another variable when the patient is already on other QT-prolonging drugs like ondansetron or methadone.
What Doesn't Work and Why
The biggest mistake I see is assuming SGA medications will improve quality of life across the board. They can help with specific symptoms — delirium, nausea, agitation, insomnia — but they don't treat the underlying cancer, they don't reverse fatigue from the disease itself, and they don't reliably improve appetite in the way some people hope. There's a difference between olanzapine helping with nausea-related anorexia and it acting as a general appetite stimulant. The evidence for the latter is weak. Another misconception is that these drugs are safe just because they're commonly used. The risk profile changes significantly depending on the patient's condition. In someone with significant hepatic impairment, the half-life of quetiapine can extend dramatically. A standard starting dose might behave like a double dose. In someone with severe dehydration and electrolyte abnormalities, the risk of QT prolongation from any of these agents becomes much more clinically relevant. I once had a patient on methadone for cancer pain who developed delirium. We started quetiapine at 25 mg, which was appropriate. Within two days their QTc went from 440 to 510 milliseconds. The methadone was the bigger contributor but the quetiapine added to it. We switched to a lower dose and monitored closely. That's the kind of interaction that requires actual clinical judgment rather than protocol-following.
Practical Monitoring
Before starting, check a baseline ECG if there's any reason to think about QT risk. Basic metabolic panel, liver function tests, and fasting glucose if you expect the treatment to last more than a few weeks. Then recheck based on the clinical situation. Most patients in acute palliative settings are on these for relatively short periods, so the metabolic monitoring is less intensive than in chronic psychiatric use. Watch for orthostatic hypotension, especially with quetiapine in volume-depleted patients. It's easy to miss if you don't check sitting and standing blood pressure. Watch for excessive sedation that could mask worsening delirium or signal something else entirely. And don't stop these abruptly if the patient has been on them for more than a couple of weeks — rebound agitation and insomnia are real even at low doses. The evidence base for SGA use in cancer patients is growing but it's not as robust as we'd like. Most studies are small, many are retrospective, and the populations vary widely. That doesn't mean these medications aren't useful — they clearly are for the right indications. It just means you need to understand what the data actually supports and where you're extrapolating based on clinical experience rather than randomized trials.
